Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| VMO | 8.73 | 0.12 | +1.39% |
| Invesco Municipal Opportunity Trust | |||
| MINN | 20.96 | 0.18 | +0.87% |
| Mairs & Power Minnesota Municipal Bond ETF (MINN) | |||
| PEX | 22.20 | 0.09 | +0.43% |
| ProShares Global Listed Private Equity ETF (PEX) | |||
| FLCC | 37.03 | 0.05 | +0.14% |
| Federated Hermes MDT Large Cap Core ETF (FLCC) | |||
| LMBS | 48.69 | 0.03 | +0.07% |
| First Trust Low Duration Opportunities ETF (LMBS) | |||
A.I.dvisor indicates that over the last year, TRDA has been closely correlated with ENGN. These tickers have moved in lockstep 78% of the time. This A.I.-generated data suggests there is a high statistical probability that if TRDA jumps, then ENGN could also see price increases.
| Ticker / NAME | Correlation To TRDA | 1D Price Change % | ||
|---|---|---|---|---|
| TRDA | 100% | -11.64% | ||
| ENGN - TRDA | 78% Closely correlated | -4.12% | ||
| INSM - TRDA | 44% Loosely correlated | -1.80% | ||
| PHAR - TRDA | 43% Loosely correlated | -0.94% | ||
| KRRO - TRDA | 42% Loosely correlated | -5.98% | ||
| ARQT - TRDA | 41% Loosely correlated | -0.50% | ||
More | ||||
Industry Biotechnology
TRDA moved below its 50-day moving average on September 15, 2026 date and that indicates a change from an upward trend to a downward trend. In 39 of 43 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TRDA as a result. In 75 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The 10-day moving average for TRDA crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for TRDA entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for TRDA's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +2.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRDA advanced for three days, in 261 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
TRDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.038) is normal, around the industry mean (26.782). P/E Ratio (10.259) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (61.350) is also within normal values, averaging (437.542).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. TRDA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRDA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.